Stock Markets April 13, 2026 12:17 PM

US IPO Candidates Press On With Roadshows as Market Swings Persist

Issuers from biotech to REITs advance listing plans while analysts say activity may recover if volatility eases

By Derek Hwang
US IPO Candidates Press On With Roadshows as Market Swings Persist

A number of companies across different industries initiated initial public offering roadshows on Monday, moving forward with planned listings despite geopolitical tensions in the Middle East and recent market turbulence. Analysts view the slate of filings and roadshows as a sign of latent supply waiting for stability, noting that recent declines in the VIX and disciplined pricing could support a gradual rebound in IPO activity.

Key Points

  • Multiple companies across sectors, including Yesway nL4N40W0YD, Alamar Biosciences, Kailera Therapeutics nL4N40W0NV and National Healthcare Properties nL4N40W0QQ, began IPO roadshows or disclosed terms on Monday.
  • Analysts note a substantial cohort of pre-IPO firms waiting for market stability; the VIX falling below 20 last week is viewed as a sign of reduced near-term volatility.
  • The near-term pipeline expanded after six companies from defense nL4N40T0XH to REIT nL4N40T1JE filed on Friday, and Pershing Square launched a roadshow nL4N40W0RT for two U.S. IPOs tied to Bill Ackman’s entities.

Several companies across disparate sectors began marketing their planned initial public offerings on Monday, signaling that a subset of issuers is prepared to proceed with public listings even as markets contend with geopolitical uncertainty tied to the Middle East conflict.

Among the firms that disclosed terms or kicked off roadshows were convenience store operator Yesway nL4N40W0YD, proteomics business Alamar Biosciences, obesity drug developer Kailera Therapeutics nL4N40W0NV and real estate investment trust National Healthcare Properties nL4N40W0QQ. These launches came as market participants weigh the outlook for volatility and investor demand ahead of potential listings.

“It speaks to the volume of pre-IPO companies waiting on the sidelines. A number of issuers just need to see some sign of stability and they’ll launch their offerings,” said Matt Kennedy, senior strategist at Renaissance Capital, which tracks IPO activity and provides related ETFs. The comment underscored that there is a pipeline of candidate listings that have been deferring market entry pending clearer conditions.

Market sentiment has shown some easing in recent sessions. The VIX Volatility Index, a commonly used measure of market fear, moved below 20 last week for the first time in over a month - a threshold some investors interpret as a sign of calmer conditions. That decline coincides with renewed attempts by certain issuers to engage prospective investors directly through roadshows.

Optimism among IPO observers has not vanished. Lukas Muehlbauer, an associate at IPOX Research, said the year remains on pace for a meaningful rebound in offerings: “2026 is still on track to be the best year for IPOs since the post-pandemic drought, and it may even get there without the mega listings. Disciplined pricing and attractive valuations make this a ’buyer’s market’, giving those deals a stronger chance of trading well after listing.”

The near-term pipeline received a boost after six companies from sectors ranging from defense nL4N40T0XH to REIT nL4N40T1JE publicly filed for IPOs on Friday, adding to the roster of potential listings that investors and underwriters are monitoring.

Nonetheless, uncertainty has not been fully resolved. Weekend diplomatic talks between the U.S. and Iran failed to produce an agreement to end the conflict, a development that leaves geopolitical risk as a continuing variable for both markets and issuers. Separately, investor-focused presentations also resumed for high-profile vehicles: Bill Ackman’s Pershing Square initiated a roadshow nL4N40W0RT for the U.S. IPOs of his management company and a new fund.

For issuers contemplating entry to public markets, the current environment presents a mix of opportunity and caution. Market participants say that if volatility remains subdued and valuations stay attractive, the pipeline of pre-IPO companies could translate into a steady cadence of listings in the months ahead. If instability returns, however, some issuers may yet choose to delay or adjust terms.


Market context and near-term outlook: A cluster of roadshows and filings suggests supply is ready to move once conditions look stable; VIX readings below 20 and disciplined deal pricing are cited as supportive factors. Geopolitical risk and episodic volatility remain the main variables that could affect timing and reception of upcoming offerings.

Risks

  • Ongoing geopolitical tensions - Weekend talks between the U.S. and Iran failed to produce a deal, leaving the Middle East conflict as a continuing source of market uncertainty that could delay or disrupt planned IPOs.
  • Market volatility - Although the VIX recently dipped below 20, episodic swings tied to macro or sector-specific news could deter issuers or depress debut valuations, affecting sectors such as biotech and real estate.
  • Issuer timing and reception - Even with a visible pipeline, companies may still postpone listings if investor appetite weakens, with impacts on both smaller growth companies and REITs seeking favorable pricing.

More from Stock Markets

Stellantis to Withdraw From Symbio Hydrogen Venture, Incurring €235 Million Charge Apr 13, 2026 AI-driven demand for power stalls progress on cleaning the air in St. Louis Apr 13, 2026 Goldman Sachs Flags Energy Names and Alternative Managers as Oil Jumps to $100 Apr 13, 2026 Texas Attorney General Opens Probe Into Lululemon Over Possible PFAS in Activewear Apr 13, 2026 Manulife Investment Management in confidential talks to buy Cellnex Swiss unit stake, sources say Apr 13, 2026